General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -0.26 | -0.26 | N/A | N/A |
2024-02-15 | 2023-12 | -0.31 | -0.27 | 0.04 | 12.90% |
2023-10-30 | 2023-09 | -0.3 | -0.27 | 0.03 | 10.00% |
2023-08-02 | 2023-06 | -0.34 | -0.26 | 0.08 | 23.53% |
2023-05-02 | 2023-03 | -0.33 | -0.31 | 0.02 | 6.06% |
2023-02-16 | 2022-12 | -0.35 | -0.35 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-15 | Piper Sandler | Upgrade | Neutral | Neutral |
2023-09-28 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-09-27 | Bernstein | Upgrade | Outperform | |
2023-09-25 | Cantor Fitzgerald | Upgrade | Neutral | Neutral |
2023-08-21 | Cantor Fitzgerald | Upgrade | Neutral | Neutral |
2023-08-03 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-02-21 | EIDEL JEFF | Officer | 893.57K | Stock Award(Grant) |
2023-03-14 | ERICSON WILLIAM W | Director | 18.80K | Sale |
2024-05-19 | FARMER MICHELE CPA | Officer | 211.94K | Sale |
2022-03-01 | FROMEN PETER | Officer | 190.28K | Stock Award(Grant) |
2024-03-03 | HENRY CHRISTIAN O | Chief Executive Officer | 2.60M | Sale |
2024-03-03 | KIM SUSAN G | Chief Financial Officer | 712.26K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK Investment Management, LLC | 29.82M | 249.02M | 11.90% |
2023-06-29 | Vanguard Group Inc | 23.13M | 307.59M | 9.23% |
2023-06-29 | Blackrock Inc. | 20.82M | 276.94M | 8.31% |
2023-06-29 | Madrone Advisors, LLC | 16.42M | 218.33M | 6.55% |
2023-06-29 | Nikko Asset Management Americas, Inc. | 13.65M | 181.54M | 5.45% |
2023-06-29 | Sumitomo Mitsui Trust Holdings, Inc. | 13.65M | 181.54M | 5.45% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK ETF Tr-ARK Innovation ETF | 16.06M | 134.09M | 6.41% |
2023-09-29 | ARK ETF Tr-ARK Genomic Revolution ETF | 11.56M | 96.50M | 4.61% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 7.19M | 95.61M | 2.87% |
2023-06-29 | Smallcap World Fund | 6.50M | 86.50M | 2.60% |
2023-06-29 | Vanguard Small-Cap Index Fund | 5.81M | 77.22M | 2.32% |
2023-08-30 | iShares Russell 2000 ETF | 5.74M | 64.77M | 2.29% |
$BNGO does gene mapping. $PACB does gene sequencing, specifically Next Generation Sequencieng (NGS). A sequence spells out the order of every DNA base in the genome, while a map simply identifies a series of landmarks in the genome. They are complementary and have different uses. If approved by the FDA, the Saphyr system will replace current processes for cytogenetics (karyotyping, FISH analysis, and chromosomal microarray). It will not replace clinical processes that require whole genome sequencing, such as CRISPR-Cas9 gene editing. $BNGO has filed a patent to develop a sequencer, but has announced it is not on their roadmap for the future at this time.
Revenues for NGS are expected to grow at an annual rate of 43%, from $3.5 billion last year to $21 billion in 2024. Genome sequencing is set to explode as the cost comes down. If you think $ILMN is going to stay on top in the sequencing market, go ahead and invest in that and good luck. I don’t think the market shares your sentiment.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads down to that of $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
The only reason Ark sells $PACB is to keep the portfolio weighting in line as it continues to grow. They do the same thing with Tesla. If you notice, it’s very small portions and their thesis has not changed. When they closed out their $ILMN position, they sold large chucks at a time. There is a difference.
What’s with all the gay bears on this board?
BNGO does gene mapping. PACB does gene sequencing, specifically Next Generation Sequencieng (NGS). A sequence spells out the order of every DNA base in the genome, while a map simply identifies a series of landmarks in the genome. They are complementary and have different uses. If approved by the FDA, the Saphyr system will replace current processes for cytogenetics (karyotyping, FISH analysis, and chromosomal microarray). It will not replace processes that require sequencing.
Revenues for NGS are expected to grow at an annual rate of 43%, from $3.5 billion last year to $21 billion in 2024. Genome sequencing is set to explode as the cost comes down. If you think $ILMN is going to stay on top in the sequencing market, go ahead and invest in that and good luck. I don’t think the market shares your sentiment.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads down to that of $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
The only reason Ark sells $PACB is to keep the portfolio weighting in line as it continues to grow. They do the same thing with Tesla. If you notice, it’s very small portions and their thesis has not changed. When they closed out their $ILMN position, they sold large chucks at a time. There is a difference.
It’s not going to take much work for $PACB to dethrone $ILMN once $PACB gets the cost of HiFi reads to the same cost as $ILMN short reads. By 2025, Ark believes both will cost about the same, being at or around $100-$500 for a full human genome. Pacific Biosciences has also mentioned that it is targeting to achieve a 30-fold improvement in the current throughput within a couple of years.
$BNGO does gene mapping. $PACB does gene sequencing, specifically Next Generation Sequencieng (NGS). A sequence spells out the order of every DNA base in the genome, while a map simply identifies a series of landmarks in the genome. They are complementary and have different uses. If approved by the FDA, the Saphyr system will replace current processes for cytogenetics (karyotyping, FISH analysis, and chromosomal microarray). It will not replace processes that require sequencing.
Revenues for NGS are expected to grow at an annual rate of 43%, from $3.5 billion last year to $21 billion in 2024. If you think $ILMN is going to stay on top in the sequencing market, go ahead and invest in that and good luck. I don’t think the market share your sentiment. Genome sequencing a set set to explode as the cost comes down.
$PACB $BNGO Brennan is unaware that Simon isn’t the only analyst covering genomics at Ark. The other analyst works part time in a genomics lab with CRISPR gene editing. I’m guessing they did more due diligence than Brennan is capable of in the last few months since he learned about genomics. Of course Brennan will never admit he’s wrong, because he’s a narcissist. He’s so insecure and so deeply needs to be right that he will bully, explain, justify, rationalize and attempt to project his view point onto others. He must have everyone agree with him or that some how invalidates him in his mind. We don’t want to hear it anymore. Go away and stay off the $PACB board. You are not welcome.
$ARKG invests in $PACB because it is poised to take market share away from $ILMN and possibly over take them in market share. $PACB HiFi reads are long reads that are not that much shorter than $ILMN long reads, but are cheaper and significant more accurate. Based on the cost to trajectory, HiFi reads will soon cost the same as $ILMN short reads, which are currently the most cost effective option for sequencing. Illumina has a 70% global market share. That is the disruption and market potential. $ILMN knew this and tried to buy $PACB but the deal was blocked due to monopoly concerns. That’s also why $ARKG sold their entire position of $ILMN, which used to be one of their largest holdings.
Brennan your pessimism and ignorance about $PACB makes me all the more excited to own it this early. It means there are others out there that think the same thing, which equals a lot of money on the table to be made.
Maybe if we all posted “Brennan eats guys” then he would stop.
Bimbo Brennan is his stripper name
Brennan the bingo boy is teaching us about genomics! Yes, tell us more professor.